Gene therapy biotech looking to bypass viral delivery wins investor approval, bagging Series A

The viral vectors that carried the first generation of gene therapies into the clinic have proven to be a troublesome lot for a variety of reasons. And now one of the biotechs brewing new ways to circumvent those obstacles in gene therapy 2.0 has a major new funding round to…